The best way to schedule an appointment is by calling us during office hours.
Location
Office Hours
Monday - Friday
9AM - 5PM
Contact
+1 (415) 600-1051
Dr. Sheridan is renowned for his expertise in surgical approaches to the treatment of cardiovascular diseases. At California Pacific Medical Center, he serves as the Chief of Cardiothoracic surgery as well as Surgical Director of Heart Transplantation and Mechanical Circulatory Support. His clinical focus is the surgical treatment of high-risk and advanced heart failure patients.
This includes the review, selection and management of patients for reconstructive cardiac intervention, ventricular assist devices (durable or temporary) and/or heart transplantation. During his 14 years of educating the next generation of cardiothoracic residents, he served as Co-principal investigator on a National Institutes of Health sponsored research grant to examine optimal strategies for treating the elderly following myocardial infarction.
He helps lead surgical teams in advanced heart failure therapeutic trials, bringing notable clinical advances in ventricular assist devices and heart transplantation to patients in the Bay Area.
Primary research topics include:
A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR) and who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team.
A Prospective, Single-arm, Controlled, Multicenter Study to Establish the Safety and Effectiveness of the CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement
Early Feasibility Study of the Edwards Lifesciences SAPIEN M3 System for the Treatment of Mitral Regurgitation (MR)
This clinical trial is a prospective, randomized, controlled, multi-center study. Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 THV or clinical surveillance. Patients will be stratified by whether or not they are able to perform a treadmill stress test. Patients who have a positive stress test will be followed in a registry to collect data on subsequent treatment and outcome.
Prospective, randomized, controlled, multi-center trial. Patients having an operative mortality < 4% (low operative risk) for surgical aortic valve replacement will be randomized 1:1 to receive either transcatheter heart valve replacement (TAVR) with the Edwards SAPIEN 3 or aortic valve replacement with a commercially available surgical bioprosthetic valve.
Early feasibility study to evaluate the safety and function of the Edwards EVOQUE transcatheter mitral valve replacement system
The study is an observational, single group study, post market study is intended to characterize hemodynamic-guided management of patients with an existing left ventricular assist device (LVAD) to protocol specified target ranges and its impact on functional status, quality of life, and readmissions, where all participants receive the same intervention. The study plans to enroll up to 100 patients at 25 US sites. All patients will have a HeartMate Left Ventricular Assist Device (LVAD) and a CardioMEMS device implanted as standard of care. After enrollment into the study, the patient will be followed until six month follow up completion. The objective of this clinical investigation is to understand the role of hemodynamic monitoring in LVAD patients and:
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including HF patients outside of the present indication, but at risk for future HF events or mortality. The trial includes patients with New York Heart Association (NYHA) Class II, III, or IV HF who have an elevated N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) (or an elevated Brain Natriuretic Peptide (BNP)) and/or a prior HF hospitalization (HFH).
The main objective of this Post-Approval Study is to report the composite endpoint of survival to transplant, recovery, or LVAD support free of stroke or reoperation to replace the pump at 5-years post-implant in subjects who were implanted with the HM3 or HMII LVAS in the MOMENTUM 3 IDE trial and are ongoing at the 2-year follow-up.
To evaluate safety and effectiveness of the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Sets for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with severe aortic stenosis who are considered at intermediate risk for surgical valve replacement including those who have a bicuspid native valve.
Left Atrial Septostomy as a Stress Test for Right Ventricular Function to Determine LVAD Candidacy.
Pump Position Impacts HeartMate II Left Ventricular Assist Device Thrombosis.
Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure.
Hemodynamics of Left Ventricular Assist Device Implantation.
Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device.
A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure.
Prevention of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study.
Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol.
Comparison of 30-Day Outcomes of Transfemoral Versus Transapical Approach for Transcatheter Aortic Valve Replacement: A Single-Center US Experience.
Reduction in driveline infection rates: Results from the HeartMate II multicenter silicone-skin-interface (SSI) registry.
Heartmate II inflow cannula migration does not predict late-term complications.
A novel link between G6PD deficiency and hemolysis in patients with continuous-flow left ventricular assist devices.
A left atrial mass in a middle-aged woman: Just another myxoma?
Resource use trajectories for aged Medicare beneficiaries with complex coronary conditions.
Disappearing and reappearing differences in drug-eluting stent use by race.
Heartmate II inflow cannula position on chest x-ray predicts inotrope dependence.
Emergency bedside thoracotomy.
Strategies for multivessel revascularization in patients with diabetes.
Stress imaging use and repeat revascularization among Medicare patients with high-risk coronary artery disease.
Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation.
Evaluating the effectiveness of a rapidly-adopted cardiovascular technology with administrative data: The case of drug-eluting stents for acute coronary syndromes.
Dynamic mitral regurgitation without regional wall motion abnormality.
Myocardial viability and survival in ischemic left ventricular dysfunction.
Coronary-artery bypass surgery in patients with left ventricular dysfunction.
Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients
Risk-benefit trade-offs in revascularisation choices.
Laparoscopic splenectomy despite the presence of a left ventricular assist device.
Three-year outcomes of multivessel revascularization in very elderly coronary syndrome patients.
Accounting for heterogeneity in treatment selection: the case of revascularization.
Coronary artery bypass surgery.
Cardiac transplantation and mechanical circulatory support devices.
Surgical treatment of valvular disease.
Congenital coronary anomalies.
Drug-eluting stents versus bare metal stents for Medicare beneficiaries with acute coronary syndromes: Instrumental variables compared to propensity scores.
Contributions of extravascular and intravascular cells to fibrin network formation, structure and stability.
Coronary bypass surgery with or without surgical ventricular reconstruction.
Percutaneous coronary intervention or coronary artery bypass grafting: Intervention in older persons with Acute Coronary Syndrome – Part II.
Percutaneous coronary intervention or coronary artery bypass grafting: Intervention in older persons with Acute Coronary Syndrome – Part I
Outcomes of surgical and endovascular treatment of acute traumatic thoracic aortic injury.
Off-pump insertion of continuous flow left ventricular assist devices.
Use of the Jarvik 2000 continuous flow left ventricular assist device for acute myocardial infarction and cardiogenic shock.
Surgical therapy for heart failure.
Thrombin generation in vascular tissue.
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Human degenerative valve disease is associated with upregulation of Lrp5 receptor mediated bone formation.
Heart transplantation for progressive cardiomyopathy as a manifestation of MELAS syndrome.
Energetics and hemodynamic changes of normal and various right heart bypass (Fontan) circulations in lambs under varying respiration parameters.
Coronary artery bypass surgery, in Netter’s Cardiology.
Cardiac transplantation, in Netter’s Cardiology.
Congenital coronary anomalies, in Netter’s Cardiology.
Lobar torsion complicating bilateral lung transplantation.
So You’re Having Heart Bypass Surgery: Everything you need to know from diagnosis to recovery.
Differential inducible nitric oxide synthase expression in systemic and pulmonary vessels after endotoxin.
Independent and combined effects of inhaled nitric oxide, liquid perfluorochemical, and high- frequency oscillatory ventilation in premature lambs with respiratory distress syndrome.
Independent and combined effects of inhaled nitric oxide, liquid perfluorochemical, and high-frequency oscillatory ventilation in premature lambs with respiratory distress syndrome.
L-arginine treatment attenuates endothelial dysfunction in endotoxin-induced lung injury.
Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury.
Kinetics of Interleukin-11 release following cardiopulmonary bypass.
L-arginine inhibits LPS-induced CINC protein production and lung neutrophil accumulation.
GP 130-dependent signaling decreases endotoxin-induced pulmonary TNF-alpha and acute lung injury.
L-arginine prevents lung neutrophil accumulation and preserves pulmonary endothelial function after endotoxin.
L-arginine decreases alveolar macrophage proinflammatory monokine production during acute lung injury.
Acute and chronic effects of bilateral lung transplantation without cardiopulmonary bypass on the first transplanted lung.
Tissue specific PKC isoforms differentially mediate macrophage TNF alpha and IL-1beta production.
Endotoxin differentially impairs receptor-mediated relaxation in rat isolated pulmonary and thoracic aortic vessels.
Selective inhibition of receptor-mediated pulmonary vasorelaxation in endotoxin-induced acute lung injury.
Endotoxin differentially impairs cyclic guanosine monophosphate-mediated relaxation in the pulmonary and systemic circulations.
Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease.
Hemorrhage induces acute cardioadaptation to ischemia-reperfusion by an alpha1-adrenoceptor-mediated, protein synthesis-independent mechanism.
Pentoxyfilline attenuates pulmonary vasomotor injury.
Phosphodiesterase inhibition overcomes pulmonary vasomotor dysfunction in acute lung injury.
Protein Kinase C isoform diversity in preconditioning.
Alpha-adrenergic activation of NF Kappa mediates hemorrhage-induced cardioadaptation to ischemia-reperfusion injury.
LPS induces delayed cardiac protection against ischemia independent of myocardial and circulating TNF.
KATP channels contribute to beat- and adenosine receptor -mediated pulmonary vasorelaxation.
Surgical implications of vascular endothelial physiology.
Endotoxin-induced vascular collapse derives from KATP channel activation with resultant impairment of alpha1-adrenergic signaling.
P38 MAP kinase mediates myocardial ischemia-reperfusion injury: Improved post-ischemic recovery with SB 203580 (Cytokine suppressor anti-inflammatory drug; CSAID)
Surgical implications of vascular endothelial physiology.
Hemorrhage activated myocardial NFkB and increases tumor necrosis factor in the heart.
Antibody-mediated neutrophil depletion preserves pulmonary vasomotor function.
Microtubules regulate pulmonary vascular smooth muscle contraction.
Endotoxin stuns cGMP-mediated pulmonary vasorelaxation.
Neutrophils are required for endotoxin-induced myocardial cross-tolerance to ischemia-reperfusion injury.
Impairment of endothelial-dependent pulmonary vasorelaxation after mesenteric ischemia/reperfusion.
Neutrophil-depletion attenuates dysfunction of cGMP-mediated pulmonary vasorelaxation in endotoxin-induced lung injury.
The obligate role of protein kinase C in mediating clinically accessible cardiac preconditioning.
Vinblastine attenuates endotoxin-induced impairment of cGMP-mediated pulmonary vasorelaxation.
Magnesium is essential in mechanisms of pulmonary vasomotor control.
Cardiac preconditioning with calcium: Clinically accessible myocardial protection.
Protein kinase C mediates Ca2(+) induced cardioadaptation to ischemia-reperfusion injury.
Inhaled nitric oxide prevents pulmonary endothelial dysfunction after mesenteric ischemia-reperfusion.
Ischemic preconditioning in human and rat ventricle.
The alpha and beta isoforms of protein kinase C mediates the cardiac contractile response to exogenous calcium.
Neutrophils mediate vascular smooth muscle dysfunction in acute lung injury.
Cardiac surgical implications of calcium dyshomeostasis in the heart.
1996
Neutrophils mediate pulmonary vasomotor dysfunction in endotoxin-induced acute lung injury.
Differential effects of adenosine preconditioning on the post-ischemic rat myocardium.
The surgical anatomy of the principal nutrient vessel of the tibia.
Anesthetic and hemodynamic effects of the stereoisomers of medetomidine, an alpha 2-adrenergic agonist, in halothane-anesthetized dogs.
Contact
+1 (415) 600-1051